METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE

Smart overview of the Invention

Methods for enhancing cancer treatment efficacy are explored through a combination of adoptive cell therapy (ACT) and targeted immunocytokines. This approach involves administering an effective dose of ACT, which includes modified T cells targeting tumor-associated antigens (TAAs), alongside a targeted immunocytokine designed to improve anti-tumor responses. The combination is shown to provide significantly better outcomes compared to ACT alone or ACT combined with non-targeted immunocytokines.

Adoptive Cell Therapy (ACT)

ACT utilizes the patient's or a donor's immune cells to combat cancer. The therapy typically involves the transfer of genetically modified T lymphocytes, which can be designed to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs) specific to TAAs. CARs enable T cells to directly recognize and destroy tumor cells, while TCRs can identify tumor-specific proteins, enhancing the immune response against cancer.

Targeted Immunocytokines

Immunocytokines are engineered proteins that combine antibodies with cytokines, aiming to localize treatment at tumor sites while minimizing systemic effects. Interleukin 2 (IL-2) is a key cytokine that stimulates T cell proliferation and function but can cause serious side effects when used in high doses. The combination of IL-2 with an antibody targeting immune checkpoints, such as PD-1, may enhance therapeutic efficacy while reducing toxicity.

Benefits of Combination Therapy

The proposed methods demonstrate a notable increase in anti-tumor efficacy and duration of response when combining ACT with targeted immunocytokines. By selecting appropriate TAAs and utilizing specific immune cells, the therapy aims to improve patient outcomes significantly. Enhanced survival rates and prolonged tumor control are highlighted as key advantages over traditional monotherapies.

Potential Applications and Future Directions

This innovative approach opens avenues for further research into personalized cancer treatments. By tailoring the combination of ACT and immunocytokines based on individual patient profiles and tumor characteristics, it holds promise for developing more effective and safer cancer therapies. Continued exploration of various TAAs and checkpoint inhibitors will be essential in optimizing treatment protocols.